StocksFundsScreenerSectorsWatchlists
PTGX

PTGX - Protagonist Therapeutics Inc Stock Price, Fair Value and News

28.93USD+0.45 (+1.58%)Market Closed

Market Summary

PTGX
USD28.93+0.45
Market Closed
1.58%

PTGX Alerts

  • 3 major insider sales recently.
  • Big jump in Earnings (Y/Y)

PTGX Stock Price

View Fullscreen

PTGX RSI Chart

PTGX Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

-21.35

Price/Sales (Trailing)

28.1

EV/EBITDA

-11.52

Price/Free Cashflow

-23.8

PTGX Price/Sales (Trailing)

PTGX Profitability

EBT Margin

-212.32%

Return on Equity

-23.45%

Return on Assets

-22.06%

Free Cashflow Yield

-4.2%

PTGX Fundamentals

PTGX Revenue

Revenue (TTM)

60.0M

PTGX Earnings

Earnings (TTM)

-79.0M

Earnings Growth (Yr)

179.94%

Earnings Growth (Qtr)

180.15%

Breaking Down PTGX Revenue

Last 7 days

-0.2%

Last 30 days

1.6%

Last 90 days

26.2%

Trailing 12 Months

39.6%

How does PTGX drawdown profile look like?

PTGX Financial Health

Current Ratio

16.71

PTGX Investor Care

Shares Dilution (1Y)

13.65%

Diluted EPS (TTM)

-1.4

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202300060.0M
202246.9M45.5M35.2M26.6M
202131.2M27.2M24.4M27.4M
202020.0M22.8M25.7M28.6M
201921.7M014.2M17.1M
201831.3M42.5M39.9M30.9M
201700020.1M

Tracking the Latest Insider Buys and Sells of Protagonist Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 07, 2024
selick harold e
acquired
12,266
1.89
6,490
-
Mar 01, 2024
waddill william d.
sold
-406,636
31.34
-12,975
-
Mar 01, 2024
patel dinesh v ph d
sold
-948,600
31.62
-30,000
president and ceo
Mar 01, 2024
waddill william d.
acquired
79,017
6.09
12,975
-
Mar 01, 2024
ali asif
acquired
146,040
12.17
12,000
chief financial officer
Mar 01, 2024
ali asif
sold
-459,318
32.2374
-14,248
chief financial officer
Feb 29, 2024
ali asif
sold
-305,048
30.692
-9,939
chief financial officer
Feb 26, 2024
patel dinesh v ph d
sold (taxes)
-322,320
29.53
-10,915
president and ceo
Feb 26, 2024
gupta suneel
sold (taxes)
-126,447
29.53
-4,282
chief development officer
Feb 15, 2024
patel dinesh v ph d
sold (taxes)
-104,931
28.23
-3,717
president and ceo

1–10 of 50

Which funds bought or sold PTGX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
reduced
-95.65
-1,803
115
-%
Mar 21, 2024
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
sold off
-100
-1,467,840
-
-%
Mar 11, 2024
VANGUARD GROUP INC
reduced
-2.31
18,469,700
72,319,300
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
120
15,835,000
23,628,000
-%
Mar 01, 2024
READYSTATE ASSET MANAGEMENT LP
reduced
-68.97
-1,763,170
1,311,730
0.04%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.4
175,520
650,983
-%
Feb 26, 2024
PERCEPTIVE ADVISORS LLC
reduced
-63.65
-8,797,120
8,788,150
0.20%
Feb 20, 2024
EVENTIDE ASSET MANAGEMENT, LLC
sold off
-100
-5,337,600
-
-%
Feb 20, 2024
Quarry LP
new
-
17,198
17,198
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
new
-
454,000
454,000
0.04%

1–10 of 46

Are Funds Buying or Selling PTGX?

Are funds buying PTGX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own PTGX
No. of Funds

Unveiling Protagonist Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
citadel advisors llc
0.0%
6
SC 13G/A
Feb 14, 2024
biotechnology value fund l p
5.4%
3,120,957
SC 13G/A
Feb 14, 2024
rtw investments, lp
9.2%
5,315,514
SC 13G/A
Feb 14, 2024
point72 asset management, l.p.
4.5%
2,613,453
SC 13G/A
Feb 13, 2024
vanguard group inc
5.47%
3,153,916
SC 13G/A
Feb 07, 2024
adage capital partners gp, l.l.c.
2.24%
1,291,701
SC 13G/A
Feb 02, 2024
farallon capital partners, l.p.
0.7%
386,653
SC 13G/A
Jan 24, 2024
blackrock inc.
9.6%
5,543,902
SC 13G/A
Jan 23, 2024
state street corp
4.73%
2,729,929
SC 13G/A
Dec 18, 2023
point72 asset management, l.p.
5.5%
3,186,077
SC 13G

Recent SEC filings of Protagonist Therapeutics Inc

View All Filings
Date Filed Form Type Document
Mar 11, 2024
4
Insider Trading
Mar 01, 2024
144
Notice of Insider Sale Intent
Mar 01, 2024
144
Notice of Insider Sale Intent
Mar 01, 2024
144
Notice of Insider Sale Intent
Mar 01, 2024
4
Insider Trading
Mar 01, 2024
4
Insider Trading
Mar 01, 2024
4
Insider Trading
Feb 29, 2024
144
Notice of Insider Sale Intent
Feb 28, 2024
4
Insider Trading
Feb 28, 2024
4
Insider Trading

Peers (Alternatives to Protagonist Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.7B
6.8B
10.47% -29.37%
-8.64
5.95
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.8B
1.8B
-5.20% -21.33%
-42.76
10.3
76.23% 61.08%
16.5B
2.4B
-4.27% -3.75%
98.3
6.81
15.42% 18.43%
12.8B
3.7B
-5.97% -18.88%
21.4
3.46
8.87% 75.42%
MID-CAP
7.1B
396.6M
-14.15% -6.74%
-13.41
17.87
425.83% 18.94%
5.4B
-
-9.06% 107.52%
-8.32
60.35
54.84% -34.79%
3.8B
270.6M
1.09% 28.79%
-15.8
13.97
440.80% -27.84%
3.5B
240.7M
-9.47% 17.74%
-11.94
14.72
-1.03% -92.09%
3.0B
726.4M
-25.38% 1.37%
-49.71
4.19
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
13.53% -1.12%
26.31
4.72
85.90% -14.05%
669.0M
983.7M
-9.64% -20.86%
-1.23
0.68
-50.36% 17.16%
411.7M
881.7K
52.39% 472.85%
-9.23
466.16
-77.61% -5.33%
324.4M
4.9M
76.14% 20.49%
-2.4
66.66
-54.97% 51.72%
14.1M
2.1M
238.33% 93.33%
-0.52
2.14
-13.45% 66.37%

Protagonist Therapeutics Inc News

Latest updates
Simply Wall St21 Mar 202401:03 pm

Protagonist Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q12018Q42018Q32018Q22018Q12017Q4
Revenue---19,000859,00025,722,0008,617,00010,286,0002,265,0006,189,0005,650,00013,114,0006,217,0003,647,0003,894,0004,141,0001,560,0002,353,0006,117,00011,674,00010,781,00011,282,000
Operating Expenses1.2%36,951,00036,516,00032,303,00042,302,00046,833,00045,633,00044,212,00033,147,00030,210,00024,480,00020,886,00024,434,00023,344,00020,018,00021,308,00016,208,00017,765,00015,506,00020,913,00019,010,000-
  S&GA Expenses21.4%8,052,0006,632,0006,901,0007,691,00010,515,0007,260,0007,256,0006,715,0005,965,0004,994,0004,891,0004,177,0004,576,0004,107,0004,015,0003,764,0003,516,5003,361,0003,178,0003,642,000-
  R&D Expenses-3.3%28,899,00029,884,00025,402,00034,611,00036,318,00038,373,00036,956,00026,432,00024,245,00019,486,00015,995,00020,257,00018,768,00015,911,00017,293,00012,444,00014,248,50012,145,00017,735,00015,368,000-
EBITDA Margin55.7%-2.11-4.75-3.54-2.74-2.66-4.56-4.35-2.94-2.16------------
Interest Expenses----------127,00019,000209,000243,000--------
Income Taxes----------5,000-1,100,000200,000817,500-100,000183,000-799,000----
Earnings Before Taxes-------36,907,000-33,804,000-30,842,000-23,998,000-18,886,000-7,763,000-18,292,000-19,904,000-16,644,500-16,511,000-13,920,000-14,664,000-8,735,000-8,663,000-7,661,000-
EBT Margin55.7%-2.12-4.79-3.57-2.76-2.68-4.59-4.41-2.99-2.21------------
Net Income179.9%27,335,000-34,194,000-31,232,000-41,037,000-20,930,000-36,907,000-33,804,000-30,842,000-23,998,000-18,886,000-7,763,000-19,421,000-20,080,000-17,501,000-16,409,000-14,103,000-13,865,000-8,735,000-8,663,000-7,661,000-
Net Income Margin72.5%-1.32-4.79-3.70-2.92-2.61-4.59-4.41-2.99-2.25-2.31-----------
Free Cashflow153.4%16,941,000-31,705,000-25,363,000-13,925,000-37,939,000-27,135,000-28,735,000-24,200,000-28,896,000------------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets8.5%358330320240248282311348348373404298324217225135155155148132139
  Current Assets9.4%356325317236243277304342341328372286316204217126145144137123138
    Cash Equivalents-19.0%18723123512812615312098.0012412119283.0011884.0014660.0033.0050.0071.0070.0083.00
  Net PPE-15.9%1.001.001.001.002.002.002.002.002.002.002.001.001.001.002.002.002.002.002.002.001.00
Liabilities-23.7%21.0028.0026.0024.0032.0039.0043.0047.0048.0044.0047.0039.0045.0048.0057.0072.0075.0059.0064.0031.0027.00
  Current Liabilities-23.7%21.0028.0026.0023.0031.0037.0040.0043.0044.0039.0043.0035.0040.0039.0035.0036.0035.0031.0033.0024.0026.00
  Long Term Debt----------------10.0010.00----
Shareholder's Equity11.4%33730229421621624426830230033035725928017016763.0080.0095.0084.00101113
  Retained Earnings4.2%-615-643-608-570-536-502-471-430-409-372-338-307-283-264-257-237-217-200-183-154-140
  Additional Paid-In Capital0.8%952945903787753747740733710702696567563435425300298296268256253
Shares Outstanding0.1%58.0058.0057.0051.0049.0049.0049.0049.0046.0048.0045.0044.00---------
Float---1,600---379,500---2,100---641---212--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations163.7%16,960-26,611-26,238-34,347-31,635-25,201-13,635-37,666-26,939-28,470-23,700-28,756-18,867-16,287-21,482-15,848-14,289-14,2463,670-16,662-10,135
  Share Based Compensation-2.4%6,6016,7658,3437,5845,5125,9506,8055,9355,0244,7753,9362,6601,9671,8881,9962,0482,1602,2012,0131,9792,072
Cashflow From Investing-352.0%-61,287-13,55925,7629,8263,93557,27534,734-4,47627,867-44,7077,773-6,793-74,402-54,122-5,17142,730-12,554-32,039-13,2254,1084,549
Cashflow From Financing-98.5%52735,315108,17226,46355368068016,9252,1731,381125,390979126,9817,669112,5773999,77925,23710,630390479

PTGX Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Consolidated Statements of Operations   
License and collaboration revenue$ 60,000$ 26,581$ 27,357
Revenue from Contract with Customer, Product and Service [Extensible List]License and Collaboration AgreementLicense and Collaboration AgreementLicense and Collaboration Agreement
Operating expenses:   
Research and development$ 120,161$ 126,215$ 126,006
General and administrative33,49131,73927,196
Total operating expenses153,652157,954153,202
Loss from operations(93,652)(131,373)(125,845)
Interest income14,8984,060443
Other expense, net(201)(80)(149)
Net loss$ (78,955)$ (127,393)$ (125,551)
Net loss per share, basic$ (1.39)$ (2.60)$ (2.71)
Net loss per share, diluted$ (1.39)$ (2.60)$ (2.71)
Weighted-average shares used to compute net loss per share, basic56,763,55949,042,23246,322,910
Weighted-average shares used to compute net loss per share, diluted56,763,55949,042,23246,322,910

PTGX Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 186,727$ 125,744
Marketable securities154,890111,611
Receivable from collaboration partner10,00010
Prepaid expenses and other current assets3,9605,712
Total current assets355,577243,077
Property and equipment, net1,1951,565
Restricted cash - noncurrent225225
Operating lease right-of-use asset9543,061
Total assets357,951247,928
Current liabilities:  
Accounts payable7723,640
Payable to collaboration partner369
Accrued expenses and other payables19,35824,955
Operating lease liability - current1,1412,515
Total current liabilities21,27431,179
Operating lease liability - noncurrent 1,141
Total liabilities21,27432,320
Commitments and contingencies
Stockholders' equity:  
Preferred stock, $0.00001 par value, 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.00001 par value, 90,000,000 shares authorized; 57,708,613 and 49,339,252 shares issued and outstanding as of December 31, 2023 and 2022, respectively1
Additional paid-in capital952,491752,722
Accumulated other comprehensive loss(105)(359)
Accumulated deficit(615,710)(536,755)
Total stockholders' equity336,677215,608
Total liabilities and stockholders' equity$ 357,951$ 247,928
PTGX
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
 CEO
 WEBSITEwww.protagonist-inc.com
 EMPLOYEES106

Protagonist Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Protagonist Therapeutics Inc? What does PTGX stand for in stocks?

PTGX is the stock ticker symbol of Protagonist Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Protagonist Therapeutics Inc (PTGX)?

As of Thu Mar 28 2024, market cap of Protagonist Therapeutics Inc is 1.69 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PTGX stock?

You can check PTGX's fair value in chart for subscribers.

What is the fair value of PTGX stock?

You can check PTGX's fair value in chart for subscribers. The fair value of Protagonist Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Protagonist Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PTGX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Protagonist Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether PTGX is over valued or under valued. Whether Protagonist Therapeutics Inc is cheap or expensive depends on the assumptions which impact Protagonist Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PTGX.

What is Protagonist Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Mar 28 2024, PTGX's PE ratio (Price to Earnings) is -21.35 and Price to Sales (PS) ratio is 28.1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PTGX PE ratio will change depending on the future growth rate expectations of investors.